Drug intelligence / Profile preview

adsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis combined vaccine

Development stage: Unknown
Lead developer: Beijing Minhai Biological
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Adsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis combined vaccine (DTaP-IPV) is a quadrivalent combination vaccine developed by Beijing Minhai Biotechnology (a subsidiary of Shenzhen Kangtai Biological Products). It is designed for the active immunization of infants and children against diphtheria, tetanus, pertussis, and poliomyelitis. The vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens (typically pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus types 1, 2, and 3, all adsorbed onto an aluminum-based adjuvant. By combining these antigens into a single injection, the vaccine aims to simplify the immunization schedule and improve vaccination compliance. As of 2023, the candidate is in Phase I clinical trials in China to evaluate its safety and immunogenicity compared to licensed combination vaccines.

Other names: Adsorbed acellular DTaP-IPV combined vaccineDTaP-IPV vaccine

Targets

FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)

Beyond the preview

Go deeper on adsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis combined vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis combined vaccine.

Explore the full profile